Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab
After treatment discontinuation, Dupilumab showed relatively longer efficacy than JAK1 inhibitors, resulting in a lower risk of relapse.
Authors
- Hanwen Wu
- Zhiming Li (ORCID: https://orcid.org/0000-0001-5740-9833)
- Xiaolin Ji
- Yahui Ye
- Qiuyang Xu (ORCID: https://orcid.org/0000-0001-7132-1707)
- Nali Yang
- Jiling Zhu
- Jingying Wang (ORCID: https://orcid.org/0000-0003-3286-5212)
- Zicheng Bai
- Zhenyan Li
- Yiwen Zhou
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Huzhou Central Hospital (CN)
- First Hospital of Jiaxing (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Ningbo No.6 Hospital (CN)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1111/ddg.15688
- Citations
- 4
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.02